Chronic Spontaneous Urticaria (CSU) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Chronic Spontaneous Urticaria (CSU) Market Outlook

Thelansis’s “Chronic Spontaneous Urticaria (CSU) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Spontaneous Urticaria treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Spontaneous Urticaria (CSU) Overview

Chronic spontaneous urticaria (CSU) also called chronic idiopathic urticarial is characterized by the occurrence of urticaria for 6 weeks or longer without identifiable specific triggers. The average duration of CSU is frequently reported as 5 years, but maybe longer in more severe cases specifically, in patients with concurrent angioedema. Patients with chronic urticaria (used as a proxy for CSU) experience the substantial health-related quality of life (HRQoL) and productivity impairments and increased psychological comorbidities relative to patients without chronic urticarial. CSU is the spontaneous development of signs and symptoms with no known specific trigger. CSU and CIndU may coexist in the same patient. Overall urticaria is classified as acute or chronic form based on the duration of illness. Chronic urticaria is diagnosed when the disease has been continuously or intermittently present for at least 6 weeks. The chronic and acute forms of urticaria differ in etiology, pathophysiology, and the underlying mechanism.

• The prevalence of chronic spontaneous urticaria (CSU) was estimated to be 0.75% to 1.02% cases within adults, however, ~ 30% to 55% of patients are diagnosed and symptomatic. 10% to 15% of patients are being diagnosed with mild, 29% to 31% of patients are being diagnosed with moderate and 27% to 29% patients are being diagnosed with a severe type of CSU.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: